Supplementary Materials

Supplementary tables and figures

- Table S1 The top 50 non-APDs according to the frequency of outpatient prescriptions
- Table S2 Number of patients receiving antiparkinsonian monotherapy and their MPR/PDC values
- Table S3 Characteristics and PDCs of the included patients with PD
- Table S4 Gamma regression analysis of medical costs with PDC adherence measures
- Fig. S1. Methods for measuring adherence
- Fig. S2. Screening process of included patients
- Fig. S3. Factors associated with adherence and the percentage of patients with low, medium, and high

PDC in each subgroup

- Fig. S4. Multiple linear regression for APD adherence using PDC
- Fig. S5. Medication adherence of patients with different lengths of follow-up

Generic name			
Acarbose	Esomeprazole	Nicergoline	
Amlodipine	Estazolam	Nifedipine	
Aspirin	Finasteride	Olanzapine	
Atorvastatin	Flupentixol and Melitracen	Omeprazole	
Butylphthalide	Irbesartan	Paroxetine	
Calcium Carbonate	Isosorbide Mononitrate	Rivastigmine	
Citalopram	Lactulose	Rosuvastatin	
Citicoline	Levamlodipine	Sertraline	
Clopidogrel	Lorazepam	Sodium Valproate	
Dihydroergotoxine	Mecobalamin	Sorbital	
Donepezil	Memantine	TCM ^a	
Duloxetine	Metformin	Zolpidem	
Escitalopram	Mirtazapine	Zopiclone	

Table S1 The top 50 non-APDs according to the frequency of outpatient prescriptions

Abbreviations: APD, antiparkinsonian drug; TCM, traditional Chinese medicines.

^aTCM mainly refers to 12 types of Chinese patent medicines that improve constipation, gastrointestinal disorders,

cardiocerebral circulation, and the common cold.

Table S2 Number of patients receiving antiparkinsonian monotherapy and their MPR/PDC values

Antiparkinsonian monotherapy	Patients, <i>n I</i> total <i>n</i> (%)	MPR, mean (SD)	PDC, mean (SD)
Subtotal	578/1712 (33.8)	0.59 (0.29)	0.57 (0.28)
Levodopa/benserazide	447/1712 (26.1)	0.59 (0.28)	0.57 (0.28)
Pramipexole	75/1712 (4.4)	0.52 (0.28)	0.50 (0.27)
Selegiline	20/1712 (1.2)	0.85 (0.18)	0.83 (0.20)
Piribedil	15/1712 (0.9)	0.49 (0.30)	0.48 (0.29)
Carbidopa/levodopa	7/1712 (0.4)	0.56 (0.29)	0.55 (0.30)
Amantadine	6/1712 (0.4)	0.78 (0.31)	0.68 (0.36)
Trihexyphenidyl	2/1712 (0.1)	0.20 (0.04)	0.20 (0.04)

Abbreviations: MPR, medication possession ratio; PDC, proportion of days covered; SD, standard deviation.

Characteristics	Patients, <i>n</i> (%)	PDC, Mean (SD)
Total sample	1712 (100)	0.65 (0.26)
Baseline		
Sex		
Female	736 (43.0)	0.64 (0.26)
Male	976 (57.0)	0.65 (0.26)
Age range, y		
≤44	33 (1.9)	0.70 (0.27)
45–64	529 (30.9)	0.67 (0.27)
65–74	404 (23.6)	0.66 (0.26)
75–84	616 (36.0)	0.63 (0.25)
≥85	130 (7.6)	0.59 (0.24)
Number of all medications		
1	153 (8.9)	0.50 (0.26)
2–5	998 (58.3)	0.64 (0.26)
6–10	493 (28.8)	0.71 (0.24)
11–36	68 (4.0)	0.69 (0.22)
Concurrent diseases		
Neurological diseases		
Depression: Yes	313 (18.3)	0.67 (0.25)
Depression: No	1399 (81.7)	0.64 (0.26)
Mental disorders: Yes	195 (11.4)	0.68 (0.25)
Mental disorders: No	1517 (88.6)	0.64 (0.26)
Dementia: Yes	286 (16.7)	0.63 (0.25)
Dementia: No	1426 (83.3)	0.65 (0.26)
Epilepsy: Yes	58 (3.4)	0.56 (0.31)
Epilepsy: No	1654 (96.6)	0.65 (0.26)
Sleep disorders: Yes	378 (22.1)	0.68 (0.23)
Sleep disorders: No	1334 (77.9)	0.64 (0.26)
Circulatory system diseases: Yes	710 (41.5)	0.64 (0.25)
Circulatory system diseases: No	1002 (58.5)	0.65 (0.26)
Endocrine and metabolic diseases: Yes	600 (35.0)	0.64 (0.26)
Endocrine and metabolic diseases: No	1112 (65.0)	0.65 (0.26)
Digestive system diseases: Yes	358 (20.9)	0.65 (0.24)
Digestive system diseases: No	1354 (79.1)	0.65 (0.26)
Medical insurance: Yes	1114 (65.1)	0.65 (0.26)
Medical insurance: No	598 (34.9)	0.64 (0.26)
Follow-up period		
Follow-up days, d		
≤290	565 (33.0)	0.74 (0.24)
291–800	574 (33.5)	0.54 (0.26)
≥801	573 (33.5)	0.67 (0.23)

Table S3 Characteristics and PDCs of the included patients with PD

Abbreviations: APD, antiparkinsonian drug; PD, Parkinson's disease; PDC, proportion of days covered; SD, standard deviation.

(continued on next page)

Table S3 (continued)

Characteristics	Patients, <i>n</i> (%)	PDC, Mean (SD)
Number of outpatient visits		
2–6	815 (47.6)	0.61 (0.29)
7–12	383 (22.4)	0.60 (0.23)
13–18	235 (13.7)	0.67 (0.19)
19–24	137 (8.0)	0.77 (0.15)
≥25	142 (8.3)	0.86 (0.11)
Inpatient episode: Yes	115 (6.7)	0.65 (0.24)
Inpatient episode: No	1597 (93.3)	0.65 (0.26)
Number of APDs		
1	578 (33.8)	0.57 (0.28)
2	390 (22.8)	0.64 (0.26)
3	361 (21.1)	0.67 (0.23)
4	233 (13.6)	0.73 (0.21)
5–7	150 (8.8)	0.80 (0.18)
Number of APD regimens		
1	623 (36.4)	0.57 (0.28)
2	280 (16.4)	0.65 (0.27)
≥3	809 (47.3)	0.71 (0.22)
Daily number of APDs		
1	602 (35.2)	0.60 (0.29)
>1 and ≤2	744 (43.5)	0.71 (0.22)
>2 and ≤3	289 (16.9)	0.74 (0.21)
>3 and ≤5	77 (4.5)	0.85 (0.15)

Abbreviations: APD, antiparkinsonian drug; PD, Parkinson's disease; PDC, proportion of days covered; SD, standard deviation.

Variables	APD costs	Non-APD costs	Other outpatient costs	Inpatient admission costs	Inpatient admission costs ^b
Variables	Estimate (95% CI)	Estimate (95% CI)	Estimate (95% CI)	Estimate (95% CI)	Estimate (95% CI)
Intercept	530.95 (500.43, 561.48) *°	199.99 (171.65, 228.32) *	106.67 (93.06, 120.29) *	5233.01 (3501.16, 6964.86) *	2145.23 (1062.41, 3228.05) *
Age (centered on 70 per	11.74 (5.12, 18.36) *	5.36 (4.41, 6.32) *	-18.64 (-27.5, -9.78) *	ND ^d	ND
10 increase)					
Sex (male vs female)	ND	8.15 (6.58, 9.71) *	ND	ND	-1127.85 (-1747.52, -508.18) *
Medical insurance (yes vs.	-26.79 (-50.43, -3.14) *	3.87 (3.04, 4.7) *	ND	ND	ND
no)					
PDC (centered on 0.7 per	36.49 (27.66, 45.33) *	ND	ND	2192.52 (1073.11, 3311.93) *	ND
0.3 increase)					
Number of APDs	322.52 (296.34, 348.69) *	-64.24 (-73.71, -54.77) *	ND	-1361.14 (-2079.04, -643.25) *	ND
(centered on 2 per 1					
increase)					
Number of all medications	-19.31 (-23.47, -15.15) *	183.68 (155.11, 212.26) *	ND	849.73 (254.6, 1444.87) *	1696.8 (767.71, 2625.9) *
(centered on 5 per 3					
increase)					
Circulatory diseases (yes	ND	46.15 (18.98, 73.32) *	ND	ND	ND
vs. no)					
Endocrine and metabolic	-32.29 (-46.89, -17.7) *	65.36 (28.5, 102.21) *	ND	ND	ND
diseases (yes vs. no)					
Digestive diseases (yes	66.76 (37.42, 96.1) *	ND	ND	ND	-1130.56 (-1750.55, -510.56) *
vs. no)					
Mental disorders (yes vs.	-36.18 (-53.84, -18.51) *	ND	32.21 (1.8, 62.62) *	-1736.68 (-2548.58, -924.77) *	ND
no)					
Dementia (yes vs. no)	ND	499.4 (356.1, 642.7) *	ND	-2524.18 (-4066.94, -981.42) *	-4981.13 (-7165.77, -2796.49) *
Depression (yes vs. no)	ND	109.5 (50.07, 168.92) *	ND	ND	1036.03 (-161.43, 2233.49) *
Sleep disorders (yes vs.	202.37 (156.41, 248.34) *	ND	-27.1 (-43.91, -10.3) *	ND	2189.49 (158.2, 4220.79) *
no)					
Number of inpatient	ND	ND	ND	ND	1779.82 (830.63, 2729.01) *
admission					

Table S4 Gamma regression analysis of medical costs with PDC adherence measures^a


Abbreviations: APD, antiparkinsonian drug; CI, confidence interval; MPR, medication possession ratio; ND, no data; PDC, proportion of days covered.

^aThe unit of cost in this table is U.S. dollars. The U.S. dollar data were calculated based on the average exchange rate between the U.S. dollar and Chinese yuan in 2017.

^bMPR as adherence measurement.

^{c*} indicates P<0.05.

^dSince some variables were dropped by the "backward method," these blank spaces are filled by ND.



Adherence measure and calculation equation	Calculation methods
$MPR = \frac{1}{m} \sum_{i=1}^{m} \frac{n_i T_i}{DOT_i} d$	$MPR = \frac{1}{2} \sum \left(\frac{4 \times 30}{\text{days between A and G}} + \frac{2 \times 90}{\text{days between H and K}} \right)$
$PDC = \frac{\text{days of at least one APDs applied}}{DOT}$	$PDC = \frac{\text{days between A and B} + \text{ days between C and G} + \text{ days between J and K}}{\text{days between A and K}}$

Fig. S1. Methods for measuring adherence^a

^aHypothetical example represents a patient receiving pramipexole who initiated treatment with selegiline (1-medicine add-on).

^bAPD 1 indicates pramipexole.

°APD 2 indicates selegiline.

^dThe relevant parameters in the calculation equation are described as follows: "m" is the number of APDs prescribed, ranging from 1 to 7 in this case. "n_i" is the total times of prescription for APD i. "T_i" is the supplied days of a single prescription. For selegiline and amantadine, the supplied days of a single prescription (as "T" in this formula) is 90 days, while the other six APDs' are 30 days, according to the medical insurance regulations. The MPR

was censored at one because some patients may have received the next prescription within 30 days.

Abbreviations: APD, antiparkinsonian drug; MPR, medication possession ratio; PDC, proportion of days covered.




Fig. S2. Screening process of included patients

Abbreviations: APD, antiparkinsonian drug; PD, Parkinson's disease.




Fig. S3. Factors associated with adherence and the percentage of patients with low, medium, and high PDC in each subgroup

(A) Percentage of patients with low, medium, and high PDC in different age groups

(B) Percentage of patients with low, medium, and high PDC in the subgroup with comorbid digestive system disease or epilepsy

(C) Percentage of patients with low, medium, and high PDC in the subgroup with different types of APDs

(D) Percentage of patients with low, medium, and high PDC in the subgroup with different types of all medications Abbreviations: APD, antiparkinsonian drug; PDC, proportion of days covered.




Fig. S4. Multiple linear regression for APD adherence using PDC^a

^aStepwise regression was performed. Using the backward method, insignificant variables were dropped step-by-step. Hence, significant variables with a p-value less than 0.05 are selected in the end.

Abbreviations: APD, antiparkinsonian drug; CI, confidence interval; LED, levodopa-equivalent dose; PDC, proportion of days covered.




Fig. S5. Medication adherence of patients with different lengths of follow-up (A) Percentage of patients with low, medium, and high MPR in different follow-up time subgroups (B) Percentage of patients with low, medium, and high PDC in different follow-up time subgroups Abbreviations: MPR, medication possession ratio; PDC, proportion of days covered.